Detragel gel naruzhn.prim th 40g tube

Description

Composition
Active substance:
1 g of gel contains: heparin sodium 100,0 ME, essential phospholipids 10.0 mg, 10.0 mg escin.
Excipients:
Isopropanol 300.00 mg, 85% glycerol 20.00 mg, trolamine 10.80 mg methyl parahydroxybenzoate 0.75 mg
ethyl parahydroxybenzoate 0.75 mg propyl parahydroxybenzoate 0.25 mg Carbomer 980 8.00 mg-cologne 0.70 mg, 0.40 mg rosemary oil, lavender oil 0.40 g water and 1.00 g
Description:
The clear, pale yellow gel with a characteristic odor.
Product form:
Gel for external application. For 40.0 g of aluminum into a tube, sealed membrane and a screw cap made of polypropylene.
Tube with instructions for use placed in a cardboard box.
Contraindications
Hypersensitivity to the drug, a hemorrhagic diathesis (including thrombocytopenic purpura), hemophilia, impaired integrity of the skin at the site of the drug (open wounds, ulcerative necrotic lesions), burns, eczema, skin infections
Is contraindicated for use on mucous membranes
Age up to 18 years.
Indications
Therapy symptoms of chronic venous diseases; • Varicose disease with symptoms as pain, swelling, fatigue and feeling of heaviness in the legs, nocturnal leg cramps, and with signs of telangiectasias (spider veins and spider veins) and varicose veins; • Superficial phlebitis, thrombophlebitis; 4 • Hematoma with injuries, including sports injuries and stretching; • Postoperative hematoma without violating the integrity of the skin.
Interaction with other drugs
There is currently no data on the interaction with other drugs.
The drug can not be applied to the same area of ​​skin in conjunction with other drugs for external application.
Overdose
Data on overdose of the drug available.
In case of overdose should immediately consult a doctor.
Treatment: In case of an overdose of heparin action may be neutralized with a solution of protamine sulfate.
pharmachologic effect
Pharmacological properties:
Means for venous + anticoagulant means of direct action for topical application.
Pharmacodynamics:
Combined preparation has a local anticoagulant, anti-inflammatory, antiplatelet and venotonic effect, reduces the permeability of veins, improves. Detragel® comprises three active ingredients sodium heparin, essential phospholipids and escin, which possess pharmacokinetic and pharmacodynamic synergy.
Sodium Heparin – direct anticoagulant action; due to inactivation of biogenic amines and blockage of lysosomal enzymes in the tissue, exhibits anti-inflammatory effect, accelerates the dissolution mikrotrombov in the subcutaneous capillaries, prevents thrombosis, activates the fibrinolytic system; It improves the microcirculation, promotes regeneration of connective tissue due to inhibition of hyaluronidase activity.
Essential phospholipids reduce blood viscosity due to the influence on fat metabolism, reduce platelet aggregation processes.
Estsin – venotoniziruyuschee plant origin.
Inhibits activation of lysosomal enzymes that break down proteoglycan increases the tone of the venous wall, removes venous stasis; reduces capillary permeability and fragility. Exudation decreases, reduces fluid effusion in the tissue and accelerates the resorption of existing edema. Inhibits inflammatory processes, improves, promotes tissue repair.
Pharmacokinetics:
For information on the pharmacokinetics of escin and phospholipids when used externally are absent. Heparin sodium quickly when applied topically penetrate through the epidermis and accumulating in the upper layers of the skin.
Minor amounts of sodium heparin is absorbed from the skin into the systemic circulation (less than 0.2% of the total amount applied).
The maximum concentration (Cmax) in the blood observed after 8 hours after application. After absorption biotransformed in the liver and reticuloendothelial system. Heparin sodium is derived mainly in the urine. The half-life (T1 / 2) is 12 hours. Heparin does not cross the placental barrier and is excreted in breast milk.
Thanks to its own hydrophilic and lipophilic properties, essential phospholipids promote rapid penetration of active ingredients through the sebaceous and sweat glands, which was confirmed by tests with radioisotopes.
Pregnancy and breast-feeding
So far, there were no reports of adverse effects on the mother and fetus when using the drug in pregnant women.
Use during pregnancy and lactation is possible only in cases where the expected benefit of therapy for the mother outweighs the potential risk to the fetus, so before using the drug should consult a doctor.
Conditions of supply of pharmacies
Without a prescription.
side effects
Side effects are given by the following grading: very often (> 1/10); common (> 1/100,
special instructions
Application of the gel on the mucous membranes contraindicated. should be avoided
In the case of allergic reactions, use of the drug should be discontinued immediately and seek medical advice.
Medicaments for topical use, especially after prolonged use, have a sensitizing effect. If this occurs, treatment with the drug should be discontinued and, if necessary, treatment accordingly. Prolonged use of the drug in extensive areas of the skin and simultaneous application of indirect anticoagulants (warfarin, acenocoumarol et al.) Should monitor the prothrombin time and clotting time.
Do not use the drug Detragel® with deep vein thrombosis.
Experience with the drug in children younger than 18 years of absence.
If your condition has worsened or did not improve after 15 days,
You should consult a doctor.
The effect on the ability to operate vehicles, machinery
Studies on the effect of the drug on the ability to drive and operate machinery has not been.
Storage conditions
At temperatures above 25 ° C. Keep out of the reach of children.
Dosing and Administration
For outdoor applications.
The gel was applied thinly to the problem skin area and uniformly distribute light massaging movements 2-3 times per day every day until symptoms disappear. If necessary, the gel can be applied by elastic bandages or stockings. Thrombophlebitis should avoid rubbing the gel. Contraindicated application of the gel on the mucous membranes.
Duration of treatment – no more than 15 days.
If your condition has worsened or did not improve after 15 days,
You should consult a doctor. The possibility of a longer course of treatment is determined by the doctor.
Do not exceed the recommended dose and duration of administration of the drug.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist